, Tracking Stock Market Picks
Enter Symbol:
Keryx Biopharmaceuticals, Inc. (KERX) [hlAlert]

down 23.55 %

Keryx Biopharmaceuticals, Inc. (KERX) upgraded to Overweight by JP Morgan

Posted on: Wednesday,  Jun 19, 2013  8:25 AM ET by JP Morgan

JP Morgan rated Overweight Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on 06/19/2013, when the stock price was $8.11. Since
then, Keryx Biopharmaceuticals, Inc. has lost 23.55% as of 01/12/2016's recent price of $6.20.
If you would have followed this JP Morgan's recommendation on KERX, you would have lost 23.55% of your investment in 937 days.

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/19/2013 8:25 AM Buy
as of 12/13/2013
1 Week down  -4.54 %
1 Month down  -4.09 %
3 Months up  33.58 %
1 YTD up  50.06 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/10/2008 9:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy